Cangrelor in Percutaneous Coronary Intervention: Current Status and Perspectives

Area of Science:

• Cardiology
• Pharmacology
• Interventional Cardiology

Background:

• Cangrelor is an intravenous P2Y12 receptor antagonist known for rapid and reversible action.
• It is approved for specific percutaneous coronary intervention (PCI) patient groups and recommended by ESC guidelines.

Purpose of the Study:

• To evaluate cangrelor's efficacy and safety in PCI based on CHAMPION PHOENIX trial data.
• To explore cangrelor's role in specific patient subsets and clinical scenarios.

Main Methods:

• Analysis of data from the CHAMPION PHOENIX trial and its subanalyses.
• Review of studies examining cangrelor's impact on ischemia, bleeding, stent thrombosis, and myocardial infarction.

Main Results:

• Cangrelor demonstrated improved anti-ischemic protection compared to clopidogrel without increased severe bleeding.
• Subanalyses explored its effectiveness in various PCI contexts and patient demographics.

Conclusions:

• Cangrelor is a valuable option for PCI, especially when oral P2Y12 inhibitors are not suitable.
• Further real-world data is needed to clarify its use with prasugrel or ticagrelor.